TABLE 3.

Results of multivariate Cox regression analysis of PFS in patients with PLC treated with ICIs

Characteristics	Univariate cox			Multivariate cox
	Hazard ratio	95% Cl	p‐value	Hazard radio	95% Cl	p‐value
Age (≥60 years)	0.694	0.459–1.049	0.083	0.695	0.458–1.054	0.087
Female	0.630	0.383–1.038	0.070	0.554	0.334–0.921	0.023
BMI	0.971	0.925–1.020	0.243
Drinking history	1.295	0.911–1.840	0.149
Smoking history	0.835	0.596–1.168	0.292
ECOG‐PS
1	0.928	0.654–1.316	0.674
2	1.623	0.891–2.956	0.114
Second‐line therapy	1.127	0.493–2.575	0.777
Child–Pugh Class(B)	1.011	0.665–1.537	0.959
Ascites	1.012	0.664–1.542	0.956
Comorbidity
Hypertension	0.868	0.574–1.313	0.503
Diabetes	0.902	0.539–1.510	0.694
Hepatitis B	1.571	0.902–2.739	0.111
Liver cirrhosis	1.355	0.915–2.005	0.130
Splenomegaly	1.708	1.101–2.650	0.017	1.766	1.130–2.761	0.013
Previous treatment
Surgery	1.256	0.850–1.854	0.253
Ablation	1.084	0.729–1.611	0.690
TACE	1.311	0.937–1.836	0.114
HAIC	1.347	0.860–2.111	0.194
Laboratory finding
WBC count (×109/L)	0.998	0.926–1.076	0.960
Lymphocyte count (≥1.1 × 109/L)	0.788	0.554–1.121	0.185
Neutrophil count (×109/L)	1.022	0.939–1.113	0.611
AST (U/L)	1.000	0.997–1.003	0.955
ALT (U/L)	1.001	0.998–1.004	0.511
Total bilirubin (≥34 μmol/L)	0.684	0.301–1.554	0.364
ALB (≥35 g/L)	1.058	0.739–1.513	0.759
PT (s)	1.025	0.919–1.144	0.654
AFP (≥200 ng/ml)	1.329	0.941–1.875	0.106
Platelet count (<100 × 109/L)	1.207	0.997–1.001	0.439

Abbreviations: AFP, alpha‐fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ECOG‐PS, Eastern Cooperative Oncology Group performance status; HAIC, hepatic arterial infusion chemotherapy; PT, prothrombin time; TACE, transcatheter arterial chemoembolization; WBC, white blood cell. In univariate cox, bold values indicate variables that were included in the multivariate cox regression analysis. In multivariate cox, bold values indicate statistically significance.